[Federal Register Volume 77, Number 146 (Monday, July 30, 2012)]
[Notices]
[Pages 44695-44696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-18488]


=======================================================================
-----------------------------------------------------------------------

OFFICE OF NATIONAL DRUG CONTROL POLICY


Revised Meeting Notice: Leadership Meeting on Maternal, Fetal, 
and Infant Opioid Exposure and Neonatal Abstinence Syndrome

AGENCY: Office of National Drug Control Policy.

ACTION: Revised notice.

-----------------------------------------------------------------------

SUMMARY: An ONDCP Leadership Meeting on Maternal, Fetal and Infant

[[Page 44696]]

Opioid Exposure and Neonatal Abstinence Syndrome (NAS) will bring 
together leaders in the field of policy, opioid exposed infants, pain 
treatment during pregnancy, and addiction treatment during and after 
pregnancy. The meeting will be held on Thursday, August 30th 2012 in 
the Indian Treaty Room, Eisenhower Executive Office Building, 17th 
Street and Pennsylvania Avenue NW., Washington D.C, 20500 starting at 
9:00 a.m. and concluding at 5:30 p.m. The overall objectives of the 
meeting are to review the state of science and policy and discuss the 
remaining challenges to the field concerning the upswing in maternal 
prescription drug abuse and dependence and resulting increases in 
opioid exposed babies with NAS and possibly other consequences. Misuse 
and abuse of, and dependence upon, prescription opioid drugs adversely 
affect the health of millions of Americans and their families.
    The specific conference objectives are: (1) To share research 
findings concerning the NAS epidemic and its costs; (2) to begin a 
national discussion concerning promising and best practices for 
treating opioid exposed babies; (3) to raise awareness about opioid 
misuse and dependence during pregnancy and the need for women with drug 
use disorders to access treatment through family medicine and 
gynecological practitioners, and specialty treatment providers; (4) to 
discuss legal and policy issues related to opioid using pregnant women 
and mothers including barriers to accessing treatment; (5) to promote 
awareness among regulatory agencies and insurers concerning the risks 
and benefits of opioids to developing fetuses and the likelihood of 
neonatal abstinence syndrome resulting from long term opioid use during 
pregnancy; and (6) to raise awareness about risk prevention 
opportunities among practitioners and regulators. Members of the public 
who wish to attend this meeting should telephone ONDCP's Maternal, 
Fetal, and Infant Opioid Exposure and Neonatal Abstinence Syndrome 
telephone line at (202) 395-7454 to arrange building access no later 
than Friday, August 10, 2012. Seating for members of the public is 
limited and will be assigned on a first come, first served basis.
    To Attend or For Further Information Contact: Cecelia Spitznas, 
Ph.D. at (202) 395-7454 or email [email protected].

    Dated: July 24, 2012.
Linda V. Priebe,
Deputy General Counsel.
[FR Doc. 2012-18488 Filed 7-27-12; 8:45 am]
BILLING CODE 3180-W1-P